Global Histology and Cytology Market By Type Of Examination, Histology-By Technique(Microscopy, Immunohistochemistry, Molecular Pathology, Cryostat & Microtomy) Cytology-By Technique(Microscopy, Immunohistochemistry, Molecular Pathology, Cryostat & Microtomy) By Product(Instruments And Analysis Software System, Consumable And Reagents) By Application (Drug Discovery & Designing, Clinical Diagnostics, Point-of-Care (PoC), Non-Point-of-Care, Research) By End User (Hospitals, Diagnostic Centers, Biotechnology and Pharmaceutical Industry, Other End Users) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Market Overview

The Global Histology and Cytology Market size is expected to be worth around USD 70.1 Billion by 2033 from USD 18.1 Billion in 2023, growing at a CAGR of 14.5% during the forecast period from 2024 to 2033.

Cytology involves studying cell structure, function and overall understanding within life sciences while histology examines microscopic anatomy of living organisms’ cells and tissues. Both disciplines aim to unravel the complex structures of animal and plant tissues at microscopic scale. Cytology stands out due to its rapid examination pace, precise results and cost-efficiency. Histology and cytology remain critical diagnostic tools that play an important role in screening tests to detect disease; their increased use has only amplified their relevance further. Histology and cytology serve as invaluable diagnostic tools in the detection of various infectious and cell-related conditions including cervical issues, inflammation disorders, cancer diagnosis as well as autoimmunity conditions.

Additionally, digital cytology systems are being developed by companies to aid in rapid evaluations of cytology samples. Antech Diagnostics, for example, introduced the North American Digital Cytology Scanner, in June 2021. This scanner delivers whole-slide interpretations in less than 2 hours. It also allows you to assess large quantities of samples at POC settings and reduces the time it takes to examine them.

Major factors that will drive the market over the forecast period include an increase in demand for the detection of cell and tissue characteristics and a global rise in the incidence of cell-based diseases like cancer. Integration of digital solutions in cytological diagnosis gives the advantage of the quick interpretation of primary diagnostic data. This market is growing due to immunohistochemistry’s increasing popularity for visualizing cells to diagnose a variety of diseases including cancers. Innovative immunohistochemistry instruments are being developed by a number of companies.

Key Takeaways

• Market Size: Histology and Cytology Market size is expected to be worth around USD 70.1 Billion by 2033 from USD 18.1 Billion in 2023.
• Market Growth: The market growing at a CAGR of 14.5% during the forecast period from 2024 to 2033.
• Types of Examination Analysis: The market leader was cytology, with a 71% revenue share in 2023.
• Product Analysis: Consumables and reagents were the dominant segments by 60% market share in 2023.
• Application Analysis: The segment of drug discovery and design dominated by 48% this market in 2023.
• End-Use Analysis: Hospitals dominate the Histology and Cytology Market with 34% market share.
• Regional Analysis: North America held the largest market share with over 41.1% in 2023.

Types of Examination Analysis

The market leader was cytology, with a 71% revenue share in 2023, which is expected to continue throughout the forecast period. The segment’s growth is due to the use of AI for developing advanced systems. Hologic Inc., for example, partnered with Google Cloud to integrate machine-learning technologies into its Genius Digital Diagnostics System in February 2021. This agreement aims at improving cervical cancer screening using machine learning, and Artificial Intelligence.

Early screening and detection are the keys to improving your chances of catching breast cancer. Fine Needle Aspiration Cytology, also known as FNAC, is the best way to detect breast carcinoma. FNAC is vital for the preoperative pathological evaluation and management of breast cancer.

Fine needle aspiration cytology, which is operator-dependent, is more difficult than histological analysis. Due to the relatively high incidence of breast cancer, countries with low and middle incomes are a good place for new industry participants looking to establish a market presence. It is therefore essential to reduce the mortality rate by using effective screening methods.

Papanicolaou (Pap smear), is recommended by WHO for cervical screening. This method detects cervical cancerous precursors at low cost and high rates. The market will grow if there is an increase in innovative cytology solutions for cervical cancer screening.

Modern histology technology has facilitated workflow and increased diagnostic capabilities for clinical laboratories. In addition, many companies are now focusing their efforts on integrating AI platforms into histology. Cernostics in partnership with Deciphex evaluated AI technology-based imaging tools in order to facilitate the early detection of Barrett’s esophageal cancer.

Product Analysis

Consumables and reagents were the dominant segments by 60% market share in 2023. It is expected that the segment will continue growth from 2023 to 2032. There are many consumables that are used in the histology or cytology process, including tissue sample containers and kits, fixatives, medium reagents, stain solutions, and others. The routine adoption of histology or cytology consumables is responsible for segment growth. Additionally, companies are creating cost-effective reagents and kits that will further drive the market in cytology/histology.

Biocare Medical LLC released the TIGIT [BLR047F] rabbit monoclonal antibody in collaboration with Bethyl Laboratories. It allows qualitative identification of TIGIT proteins by Immunohistochemistry. The antibody will provide a cost-effective immunohistochemistry option for institutions involved in biotech and pharmaceutical research.

Due to the increased use of technologically advanced instruments like multimodal nonlinear microscopes, photoacoustic microscopic microscopy, and stimulated Raman spectroscopy for histopathology, the instruments, and analysis system segment will see a significant increase in growth between 2023-2032. However, the large-scale adoption of digital transformational solutions in pathology has been hindered by high infrastructure costs as well as technical and practical limitations. Therefore, digitization costs will decrease in pathology.

Application Analysis

With a 48%  revenue share, the segment of drug discovery and design dominated this market in 2023. It is expected that the segment will maintain its leadership position during the forecast period. The large use of IHC staining in drug development companies and pharmaceutical companies can explain the segment’s growth. Image analysis is used across many steps of drug discovery, development, and validation such as target validation, drug efficacy, safety studies, drug repositioning, and patient stratification.

The growing use of histopathology for the diagnosis of various types of cancer is expected to drive a 13.5% CAGR in the clinical diagnostics segment. To identify abnormalities and malignancy, the cells and tissues of suspicious lump sites are removed. They are widely used in the screening of different types of cancer, including cervical, breast, and bowel cancer.

End User Analysis

Hospitals dominate the Histology and Cytology Market with 34% market share, using histology and cytology techniques for accurate patient assessments using state-of-the-art laboratories, skilled professionals and providing comprehensive histopathology/cytopathology services that address various healthcare needs.

Diagnostic centers also play a vital role in the market by offering histology and cytology services directly to patients. Their primary mission is delivering quick diagnostic results quickly to enable timely medical intervention for enhanced patient outcomes.

Biotechnology and pharmaceutical industries also contribute significantly to the histology and cytology market growth, using histology/cytology techniques for drug development, efficacy testing, safety assessments, as well as advancements in medical research/therapeutics.

Key Market Segments

Type Of Examination

Histology

By Technique

• Microscopy
• Immunohistochemistry
• Molecular Pathology
• Cryostat & Microtomy

Cytology

By Technique

• Microscopy
• Immunohistochemistry
• Molecular Pathology
• Cryostat & Microtomy

Product

• Instruments And Analysis Software System
• Consumable And Reagents

Application

• Drug Discovery & Designing
• Clinical Diagnostics
• Point-of-Care (PoC)
• Non-Point-of-Care
• Research

End User

• Hospitals
• Diagnostic Centers
• Biotechnology and Pharmaceutical Industry
• Other End Users

Regional Analysis

North America held the largest market share with over 41.1% in 2023. Many factors contributed to the region’s growth, such as high cancer incidence, extensive R&D, key players, and a well-established research infrastructure for pathology. Additionally, the market is thriving due to the high rate at which products are approved and commercialized in the region.

The Asia Pacific is expected to see the fastest growth in the market for cytology and histology between 2024-2033. Many factors have contributed to the rapid growth of this market, such as rising cancer awareness, large target populations, and improved healthcare infrastructure. Research is also accelerating the growth of this market by evaluating new forms of cytology.

In Japan, researchers evaluated the efficacy and safety of liquid-based Cytology in cervical cancer screening in February 2021. The study revealed that liquid-based, practical cytology was superior to conventional cytology.

Key Regions and Countries

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Rest of Asia-Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• MEA
  • GCC
  • South Africa
  • Israel
  • Rest of MEA

Market Players Analysis

Different solutions for cancer screening have had rapid introductions and approvals in recent years. Hologic Inc. was granted premarket approval in May 2021 by the U.S. FDA to market its Thin Prep Genesis Processor. The Thin Prep genesis processor combines sample processing and cytology with improved workflow.

Barcode scanning, automatic tube, and slide labeling are some of the features. These features reduce hands-on work and allow for repetitive motions. The company offers a large selection of products and automated testing platforms to detect cervical cancer.

Маrkеt Kеу Рlауеrѕ

• Hologic, Inc.
• BD
• Abbott
• Merck KgaA
• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific, Inc.
• Danaher
• Trivitron Healthcare
• Sysmex Corporation
• Koninklijke Philips N.V.

Recent Developments

• January 2024: Hologic, Inc. Received FDA clearance for the Panther Fusion Aptima HSV 1 & 2 Assay, a molecular diagnostic test for herpes simplex virus.
• February 2024: BD Launched the BD Accuri Cytoflex LX flow cytometer with advanced automation features.
• November 2023: Abbott Announced a partnership with Microsoft to develop AI-powered solutions for pathology workflows.
• December 2023: Merck KGaA Signed a collaboration agreement with Incellerate to develop AI-based digital pathology solutions.

Report Scope